Xvivo Perfusion AB Statistics

Total Valuation

Xvivo Perfusion AB has a market cap or net worth of SEK 15.04 billion. The enterprise value is 14.62 billion.

Market Cap	15.04B
Enterprise Value	14.62B

Important Dates

The next estimated earnings date is Tuesday, January 28, 2025.

Earnings Date	Jan 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Xvivo Perfusion AB has 31.50 million shares outstanding. The number of shares has increased by 4.55% in one year.

Current Share Class	n/a
Shares Outstanding	31.50M
Shares Change (YoY)	+4.55%
Shares Change (QoQ)	+0.22%
Owned by Insiders (%)	0.42%
Owned by Institutions (%)	44.53%
Float	25.00M

Valuation Ratios

The trailing PE ratio is 72.96 and the forward PE ratio is 91.48.

PE Ratio	72.96
Forward PE	91.48
PS Ratio	19.79
PB Ratio	7.22
P/TBV Ratio	10.31
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 155.19, with an EV/FCF ratio of -30,322.80.

EV / Earnings	71.55
EV / Sales	19.47
EV / EBITDA	155.19
EV / EBIT	252.10
EV / FCF	-30,322.80

Financial Position

The company has a current ratio of 5.49, with a Debt / Equity ratio of 0.01.

Current Ratio	5.49
Quick Ratio	4.23
Debt / Equity	0.01
Debt / EBITDA	0.26
Debt / FCF	-50.99
Interest Coverage	48.72

Financial Efficiency

Return on equity (ROE) is 10.18% and return on invested capital (ROIC) is 1.78%.

Return on Equity (ROE)	10.18%
Return on Assets (ROA)	1.60%
Return on Capital (ROIC)	1.78%
Revenue Per Employee	4.66M
Profits Per Employee	1.27M
Employee Count	160
Asset Turnover	0.33
Inventory Turnover	1.14

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +73.08% in the last 52 weeks. The beta is 2.10, so Xvivo Perfusion AB's price volatility has been higher than the market average.

Beta (5Y)	2.10
52-Week Price Change	+73.08%
50-Day Moving Average	477.18
200-Day Moving Average	425.84
Relative Strength Index (RSI)	58.18
Average Volume (20 Days)	63,575

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Xvivo Perfusion AB had revenue of SEK 750.59 million and earned 204.27 million in profits. Earnings per share was 6.54.

Revenue	750.59M
Gross Profit	558.52M
Operating Income	57.98M
Pretax Income	215.89M
Net Income	204.27M
EBITDA	83.53M
EBIT	57.98M
Earnings Per Share (EPS)	6.54

Full Income Statement

Balance Sheet

The company has 449.98 million in cash and 24.58 million in debt, giving a net cash position of 425.41 million or 13.51 per share.

Cash & Cash Equivalents	449.98M
Total Debt	24.58M
Net Cash	425.41M
Net Cash Per Share	13.51
Equity (Book Value)	2.08B
Book Value Per Share	66.13
Working Capital	677.28M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 67.33 million and capital expenditures -67.82 million, giving a free cash flow of -482,000.

Operating Cash Flow	67.33M
Capital Expenditures	-67.82M
Free Cash Flow	-482,000
FCF Per Share	-0.02

Full Cash Flow Statement

Margins

Gross margin is 74.41%, with operating and profit margins of 7.72% and 27.21%.

Gross Margin	74.41%
Operating Margin	7.72%
Pretax Margin	28.76%
Profit Margin	27.21%
EBITDA Margin	11.13%
EBIT Margin	7.72%
FCF Margin	-0.06%

Dividends & Yields

Xvivo Perfusion AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.55%
Shareholder Yield	-4.55%
Earnings Yield	1.37%
FCF Yield	-0.00%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Xvivo Perfusion AB has an Altman Z-Score of 35.73.

Altman Z-Score	35.73
Piotroski F-Score	n/a